Melissa Kane

Dr. Melissa Kane

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2013 in Nature
Verified
Journal Article
Closed access
PDF file
MKMelissa Kane
Melissa Kane
SYShalini S. Yadav
Shalini S. Yadav
JBJulia Bitzegeio
Julia Bitzegeio
SKSebla B. Kutluay
Sebla B. Kutluay
TZTrinity Zang
Trinity Zang
PBPaul D. Bieniasz
Paul D. Bieniasz

14 October 2011 in Science
Verified
Journal Article
Closed access
PDF file
MKMelissa Kane
Melissa Kane
LCLaure K. Case
Laure K. Case
KKKaryl Kopaskie
Karyl Kopaskie
AKAlena Kozlova
Alena Kozlova
CMCameron MacDearmid
Cameron MacDearmid
TGTatyana Golovkina
Tatyana Golovkina
Commensal microflora promote the pathogenesis of mucosally acquired viruses.

1 September 2016 in Cell Host & Microbe
Verified
Journal Article
Open access
MKMelissa Kane
Melissa Kane
TZTrinity M. Zang
Trinity M. Zang
SRSuzannah J. Rihn
Suzannah J. Rihn
FZFengwen Zhang
Fengwen Zhang
TKTonya Kueck
Tonya Kueck
PBPaul D. Bieniasz
Paul D. Bieniasz
Interferons (IFNs) exert their anti-viral effects by inducing the expression of hundreds of IFN-stimulated genes (ISGs). The activity of known ISGs is insufficient to account for the antiretroviral effects of IFN, suggesting that ISGs with antiretroviral activity are yet to be described. We constructed an arrayed library of ISGs from rhesus macaques and tested the ability of hundreds of individual macaque and human ISGs to inhibit early and late replication steps for 11 members of the retroviridae from various host species. These screens uncovered numerous ISGs with antiretroviral activity at both the early and late stages of virus replication. Detailed analyses of two antiretroviral ISGs indicate that indoleamine 2,3-dioxygenase 1 (IDO1) can inhibit retroviral replication by metabolite depletion while tripartite motif-56 (TRIM56) accentuates ISG induction by IFNα and inhibits the expression of late HIV-1 genes. Overall, these studies reveal numerous host proteins that mediate the antiretroviral activity of IFNs.

15 July 2014 in Journal of Virology
Verified
Journal Article
Closed access
IBIdoia Busnadiego
Idoia Busnadiego
MKMelissa Kane
Melissa Kane
SRSuzannah J. Rihn
Suzannah J. Rihn
HPHannah F. Preugschas
Hannah F. Preugschas
JHJoseph Hughes
Joseph Hughes
SWSam Wilson
Sam Wilson
Myxovirus resistance 2 (Mx2/MxB) has recently been uncovered as an effector of the anti-HIV-1 activity of type I interferons (IFNs) that inhibits HIV-1 at an early stage postinfection, after reverse transcription but prior to proviral integration into host DNA. The mechanistic details of Mx2 antiviral activity are not yet understood, but a few substitutions in the HIV-1 capsid have been shown to confer resistance to Mx2. Through a combination of in vitro evolution and unbiased mutagenesis, we further map the determinants of sensitivity to Mx2 and reveal that multiple capsid (CA) surfaces define sensitivity to Mx2. Intriguingly, we reveal an unanticipated sensitivity determinant within the C-terminal domain of capsid. We also report that Mx2s derived from multiple primate species share the capacity to potently inhibit HIV-1, whereas selected nonprimate orthologs have no such activity. Like TRIM5α, another CA targeting antiretroviral protein, primate Mx2s exhibit species-dependent variation in antiviral specificity against at least one extant virus and multiple HIV-1 capsid mutants. Using a combination of chimeric Mx2 proteins and evolution-guided approaches, we reveal that a single residue close to the N terminus that has evolved under positive selection can determine antiviral specificity. Thus, the variable N-terminal region can define the spectrum of viruses inhibited by Mx2. IMPORTANCE Type I interferons (IFNs) inhibit the replication of most mammalian viruses. IFN stimulation upregulates hundreds of different IFN-stimulated genes (ISGs), but it is often unclear which ISGs are responsible for inhibition of a given virus. Recently, Mx2 was identified as an ISG that contributes to the inhibition of HIV-1 replication by type I IFN. Thus, Mx2 might inhibit HIV-1 replication in patients, and this inhibitory action might have therapeutic potential. The mechanistic details of how Mx2 inhibits HIV-1 are currently unclear, but the HIV-1 capsid protein is the likely viral target. Here, we determine the regions of capsid that specify sensitivity to Mx2. We demonstrate that Mx2 from multiple primates can inhibit HIV-1, whereas Mx2 from other mammals (dogs and sheep) cannot. We also show that primate variants of Mx2 differ in the spectrum of lentiviruses they inhibit and that a single residue in Mx2 can determine this antiviral specificity.

7 August 2018 in eLife
Verified
Journal Article
Open access
MKMelissa Kane
Melissa Kane
SRStephanie V Rebensburg
Stephanie V Rebensburg
MTMatthew A Takata
Matthew A Takata
TZTrinity M Zang
Trinity M Zang
MYMasahiro Yamashita
Masahiro Yamashita
PBPaul D Bieniasz
Paul D Bieniasz
HIV-1 accesses the nuclear DNA of interphase cells via a poorly defined process involving functional interactions between the capsid protein (CA) and nucleoporins (Nups). Here, we show that HIV-1 CA can bind multiple Nups, and that both natural and manipulated variation in Nup levels impacts HIV-1 infection in a manner that is strikingly dependent on cell-type, cell-cycle, and cyclophilin A (CypA). We also show that Nups mediate the function of the antiviral protein MX2, and that MX2 can variably inhibit non-viral NLS function. Remarkably, both enhancing and inhibiting effects of cyclophilin A and MX2 on various HIV-1 CA mutants could be induced or abolished by manipulating levels of the Nup93 subcomplex, the Nup62 subcomplex, NUP88, NUP214, RANBP2, or NUP153. Our findings suggest that several Nup-dependent ‘pathways’ are variably exploited by HIV-1 to target host DNA in a cell-type, cell-cycle, CypA and CA-sequence dependent manner, and are differentially inhibited by MX2.

1 July 2011 in Immunity
Verified
Journal Article
Closed access
MKMelissa Kane
Melissa Kane
LCLaure K. Case
Laure K. Case
CWChristine Wang
Christine Wang
LYLeonid Yurkovetskiy
Leonid Yurkovetskiy
SDStanislav Dikiy
Stanislav Dikiy
TGTatyana Golovkina
Tatyana Golovkina